BioCryst Pharmaceuticals | BCRX - Current Liabilities


BioCryst Pharmaceuticals reported $190.24M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
BioCryst Pharmaceuticals USD 190.24M 13.08M Sep/2025
Chugai Pharma JPY 411.08B 143.65B Dec/2025
Daiichi Sankyo JPY 778.55B 77.51B Dec/2025
DBV Technologies USD 49.48M 60K Sep/2025
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Gilead Sciences USD 11.81B 485M Dec/2025
GlaxoSmithKline GBP 21.39B 57M Dec/2025
Glaxosmithkline GBP 28.68B 8.3B Sep/2025
Incyte USD 1.52B 176.44M Dec/2025
Ionis Pharmaceuticals USD 783M 120.46M Dec/2025
Karyopharm Therapeutics USD 87.16M 12.06M Sep/2025
Neurocrine Biosciences USD 743.4M 105.4M Dec/2025
Novavax USD 429.87M 40.73M Sep/2025
PTC Therapeutics USD 968.43M 102.18M Dec/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Roche Holding CHF 28B 421M Dec/2025
Sarepta Therapeutics USD 1.1B 173.86M Dec/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Vertex Pharmaceuticals USD 3.86B 614.1M Dec/2025